1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Asset Management - Cryptocurrency
Ethzilla Corp.

Ethzilla Corp.

ETHZW
Ethzilla Corp.US flagNASDAQ Global Market
0.01
USD
-0.02
- -
5,436.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
7
9
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-3,662.36
-2,622.51
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-25
-11
-20
-39
-20
-6
-451
-524
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-6,881.33
-5,575.33
Working Capital
-9
-17
-8
3
-1
2
-27
69
LT Debt
- -
- -
- -
- -
- -
- -
26
26
Total Equity
39
30
39
11
- -
9
239
168
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
50
32
1
LT Borrowings
496
26
26
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
19
20
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
562
14
83
Cash, Cash Equivalents & STI
53
8
66
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
56
41
13
Payables & Accruals
2
2
2
ST Debt
50
32
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-999.59%
2,487.74%
Free Cash Flow
- -
477.69%
2,124.77%
Net Income, GAAP
- -
1,452.77%
7,204.17%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
4
2
7
2026
3
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
McAndrew Rudisill
Full Time Employees
4
Sector
Financial Services
Industry
Asset Management - Cryptocurrency
Address
Building 4 Palo Alto FL United States of America 94306
IPO Date
Jun 27, 2017
CIK
0001690080
Website
180lifesciences.com
Similar Companies
iShares Bitcoin ETP (IB1T.PA)
Horizon Kinetics Blockchain Development ETF (BCDF)
21Shares Active Crypto ETF (TKNS)
VanEck BNB ETF Common Shares of Beneficial Interest (VBNB)
AdvisorShares Managed Bitcoin Strategy ETF (CRYP)
SmartShares - Smart Bitcoin ETF (BTC.NZ)
Business
Ethzilla Corp. operates as a biotechnology and life sciences company specializing in the development, manufacturing, and commercialization of cannabis-derived products and therapeutics. Its core product portfolio includes medical and recreational cannabis formulations; cannabinoid-based pharmaceuticals; wellness products such as oils, tinctures, and topicals; and research services focused on cannabinoid science. The company serves healthcare providers, pharmaceutical partners, and consumer wellness markets primarily across North America, with expanding operations into Europe and other international regions. Founded in 2016 and headquartered in Toronto, Canada, Ethzilla Corp. has recently undertaken significant strategic initiatives including new partnerships with pharmaceutical companies to co-develop cannabinoid drug candidates, launch of proprietary cannabinoid extraction and formulation technologies, and expansion of its product line into novel delivery systems such as transdermal patches and inhalable therapies. In the last two years, Ethzilla has also engaged in several acquisitions to broaden its research capabilities and scale manufacturing infrastructure. These moves reflect a strategic shift from solely cannabis cultivation to a diversified life sciences enterprise focused on innovation in cannabinoid therapeutics and wellness solutions. The company operates through subsidiaries dedicated to cultivation, product development, clinical research, and distribution. Ethzilla's business segments encompass pharmaceutical development, consumer wellness products, and contract research services. Its target customers include healthcare institutions, pharmaceutical companies, licensed cannabis distributors, and direct consumers. As of 2025, Ethzilla continues to invest in clinical trials to substantiate the efficacy of its drug candidates and expand regulatory approvals globally. Overall, Ethzilla Corp. is positioned as an integrated biotechnology company leveraging cannabis science for pharmaceutical innovation, consumer health products, and scientific research, supported by recent expansions and strategic alliances in its evolving industry landscape.